- Home
- Automated
- List of product information
- UROKINASE-GREEN CROSS INJ. 60,000 IU/VIAL [SIN11140P]
UROKINASE-GREEN CROSS INJ. 60,000 IU/VIAL [SIN11140P]
Active ingredients: UROKINASE-GREEN CROSS INJ. 60,000 IU/VIAL
On this page
Product Info
UROKINASE-GREEN CROSS INJ. 60,000 IU/VIAL
[SIN11140P]
Product information
Active Ingredient and Strength | UROKINASE - 60,000 INTERNATIONAL UNITS/VIAL |
Dosage Form | INJECTION, POWDER, FOR SOLUTION |
Manufacturer and Country | CHINA CHEMICAL & PHARMACEUTICAL CO., LTD. - TAIWAN |
Registration Number | SIN11140P |
Licence Holder | GRIFOLS ASIA PACIFIC PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | B01AD04 |
INDICATIONS
Treatment of the following thrombotic-occlusive diseases:
♦ Cerebral thrombosis (within 5 days after the onset of symptoms, and without hemorrhage detectable by computed tomography)
♦ Peripheral arterial-venous occlusion (within 10 days after the onset of symptoms)
DOSAGE AND ADMINISTRATION
Reconstitute the contents of one vial with 10 mL of physiological saline and inject intravenously. Preferably instill as an admixture with physiological saline or glucose injection.
[Thrombotic-occulsive diseases]
♦ Cerebral thrombosis: Administer 60,000 international units once a day for about 7 days.
♦ Peripheral arterial-venous occlusion: Administer 60,000 to 240,000 international units on first day of treatment followed by tapered doses for about 7 days.
(2) Contraindications
Patients for whom hemostatic management is difficult: intracranial hemorrhage, hemoptysis, retroperitoneal hemorrhage and the like.
Patients having undergone intracranial or spinal surgery or with such injury (in the last 2 months).
Patients with aneurysm.
Patients with serious disturbances of consciousness.
(3) Contraindications as a general rule
This product is contraindicated in the following patients, as a general rule. If essential, however, it can be administered with caution.
Patients with atrial fibrillation (particularly with mitral stenosis), patients with infective endocarditis, patients with old myocardial infarction, and patients with a prosthetic valve.
Patients with neurological signs and symptoms of stroke which became complete instantaneously.
